Parnax Lab Ltd. (BSE: 506128) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹132 Cr, it ranks #3,022 by market cap among the 6,137 Indian listed companies on FinBizNet, and #67 of 86 in Medicinal Chemicals and Botanical Products. At ₹103.50 (as of 25 Oct 2026), the share price is 30.8% below its 52-week high of ₹149.50 and 4.6% above its 52-week low of ₹98.95. The share price is down 7.8% over one year and down 7.1% over three months.
| Current Price | ₹103.50 |
|---|---|
| Market Cap | ₹132 Cr |
| BSE Code | 506128 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 10.6 |
| Return on Equity | 13.22% |
| Return on Assets | 6.62% |
| 52-Week Range | ₹98.95 – ₹149.50 |
| 1-Year Price Change | -7.8% |
| 3-Month Price Change | -7.1% |
| Beta (1Y) | 0.28 |
| Headquarters | Mumbai, Maharashtra |
| Website | www.naxparlab.com |
Parnax Lab Limited engages in the manufacture and export of pharmaceutical formulations in India and internationally. The company offers pharmaceutical products in the form of liquids, ointments, gels, creams, tablets, and capsules; cosmetic products; herbal products; and nutraceutical products. It also provides Oral Formulations, such as cough expectorants, antacids, antihistamines, multi-vitamins, enzyme preparations, pediatric formulations, formulations for geriatrics, highly viscous products, and suspensions. In addition, the company provides drug identification and development services; in- and out-licensing services; and contract research and manufacturing services The company was formerly known as Krishna-Deep Trade & Investments Limited and changed its name to Parnax Lab Limited in April 2012. The company was incorporated in 1982 and is headquartered in Mumbai, India.
1. Dealing in Pharmaceutical Formulations-This segment manufactures and sells pharmaceutical formulations.
1. Dealing in Pharmaceutical Formulations-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Parnax Lab Ltd. | ₹132 Cr | 10.6 | 13.22% | — | -7.8% |
Listed by market capitalisation. Ratios are shown for context only.
Parnax Lab Ltd. is trading at ₹103.50, with a market capitalisation of ₹132 Cr.
Parnax Lab Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Parnax Lab Ltd. has a P/E of 10.6 and a return on equity of 13.22%.
Parnax Lab Ltd. is listed on the BSE under the scrip code 506128.
Parnax Lab Ltd.'s share price is down 7.8% over one year and down 7.1% over three months. Its 52-week range is ₹98.95 to ₹149.50.
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.